Novo Nordisk and AWS unveiled a strategic partnership to accelerate drug discovery and modernize operations through AI and cloud technologies, with AWS as Novo Nordisk’s preferred cloud provider and strategic AI partner.

The collaboration emphasizes speeding medicine development and securely handling complex datasets across therapeutic areas, aiming to compress drug-discovery timelines.

Key technologies referenced include Amazon Bio Discovery, Amazon Bedrock, and Bedrock AgentCore to identify drug targets, design therapies faster, and connect diverse data sources.

Novo Nordisk is a global healthcare leader with a long history dating back to 1923, employing about 66,700 people across roughly 80 countries and marketing products in about 170 countries.

The partnership builds on a longstanding relationship and centers on turning ideas into new therapies for patients worldwide, with a focus on responsible AI development and co-innovation.

An AI co-innovation hub will be established at Novo Nordisk’s London King's Cross facility, uniting scientists, engineers, and AWS AI specialists to shorten the path from drug target to first human dose and enable real-time decision-making.

This hub aims to reduce handoff delays and enhance collaboration between computational insights and laboratory experiments through integrated AI-enabled drug development.

AWS CEO Matt Garman underlined the use of AWS tools and deployed engineers to securely process complex datasets and scale findings across therapeutic areas.

The partnership leverages AI services such as Bio Discovery and Bedrock AgentCore to enable AI-powered solutions across R&D, commercial operations, and enterprise IT, with Bedrock AgentCore supporting scalable, production-grade AI workflows.

Analysts on earnings calls highlighted investor focus on near-term revenue drivers like pricing, Medicare uptake, and commercial performance, alongside the discovery efforts.

The collaboration aligns with Novo Nordisk’s mission to defeat chronic diseases through scientific breakthroughs and expanded access to medicines.

Despite the deal, Novo faces pipeline challenges, including setbacks with CagriSema and a ZEUS trial endpoint miss, adding pressure on stock and growth outlook.